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Abstract 
Background: Overexpression and enhanced release of vascular endothelial growth factor (VEGF) have been 
detected in various types of allergic inflammation, including asthma.
Aim: To further evaluate the pattern of systemic release of VEGF in atopic allergy, free circulating VEGF was measured 
in patients with persistent allergic rhinitis (PAR).
Methods: The concentrations of VEGF and its soluble receptors (sVEGF‑R1 and VEGF‑R2) in plasma were measured in 
patients with PAR sensitized to house dust mites and the healthy subjects.
Results: No significant differences were found between PAR patients and healthy subjects with respect to plasma 
levels of VEGF and its receptors.
Conclusions: It seems that free circulating VEGF may not be elevated in PAR patients. Moreover, on the basis of the 
present study as well as the earlier ones, it appears likely that systemic release of VEGF varies among patients with 
distinct clinical manifestation of atopy; may depend on severity/activity and the extent of inflammatory response.
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Background
It has been indicated that vascular endothelial growth 
factor (VEGF) is a multifunctional cytokine, which plays 
a role in the pathogenesis of immune-inflammatory reac-
tions [1, 2]. VEGF is a powerful enhancer of vascular 
permeability and its activity is 50,000 times more potent 
than histamine [3]. In addition, VEGF may be released 
by different cells associated with allergic inflammation of 
the airways, including mast cells upon activation via the 
Fcε receptor I (FcεRI) [2, 4–6].
Interestingly, it has been demonstrated that dust-mite 
allergen may stimulate airway cells to increased VEGF 
secretion [7], which may play an important role in the 
modulation of eosinophilic inflammation [8]. There have 
been several reports describing association between 
VEGF and allergic airway inflammation. However, data 
regarding a role of VEGF in the upper-airway allergic 
diseases are scarce. In the present study, we investigated 
plasma VEGF concentration in patients with allergy to 
house dust mites, suffering from persistent allergic rhini-
tis (PAR) in the absence of asthma symptoms.
Methods
Sixteen patients with moderate to severe PAR (untreated, 
newly diagnosed) without any history of asthmatic symp-
toms (seven males, nine females; aged 18–36  years; 
median 23 years) were enrolled into the study.
They had positive skin tests to Dermatophagoides 
pteronyssinus and Dermatophagoides farinae extract 
and positive serology (specific IgE = class 2 or higher) as 
Open Access
Allergy, Asthma & Clinical Immunology
*Correspondence:  alakasperska@gmail.com 
2 Department of Internal Diseases, Dermatology and Allergology, SMDZ 
in Zabrze, Medical University of Silesia, Katowice, Poland
Full list of author information is available at the end of the article
Page 2 of 4Koczy‑Baron et al. Allergy Asthma Clin Immunol  (2016) 12:17 
well as negative response to all other common aeroaller-
gens: pollens (grasses, cereals, trees and weeds), moulds 
(Alternaria, Cladosporium, Aspergillus, Penicillium), ani-
mal danders (comprising dog, cat, rabbit and guinea pig).
The clinical diagnosis of allergic rhinitis was performed 
according to criteria reported in the ARIA document.
The patients were compared with 35 healthy non-
atopic subjects (20 males, 15 females; aged 18–38 years; 
median 21  years). None of the subjects had any other 
concomitant disorders [9].
All the subjects submitted respective written consent 
and the study was approved by the University Committee 
of Ethics.
Blood samples and analytical methods
VEGF analysis
Because platelets are potential source of VEGF, we meas-
ured VEGF concentration in platelet-poor plasma (PPP) 
according to method described previously [9].
VEGF concentrations were determined using the 
enzyme-linked immunosorbent assay (ELISA) (Quan-
tikine R&D Systems Inc. Minneapolis, MN USA). The 
detection limits were 9.0  pg/ml. Values below 9  pg/ml 
were equalized to zero.
sVEGF‑R1 and sVEGF‑R2 analyses
sVEGF-R1 and sVEGF-R2 concentrations were per-
formed in the plasma collected, using EDTA as an anti-
coagulant. The cytokines concentrations were assayed 
by specific, commercially available, ELISA assay kits 
(Quantikine R & D Systems Inc., Minneapolis, MN USA) 
in accordance with the manufacturer’s instructions. The 
sensitivity of the assay for VEGF-R1 and sVEGFR-2 was 
3.0 and 5 pg/ml, respectively.
Skin prick tests
Allergic status was evaluated using a panel of common 
inhalant (Allergopharma, Reinbeck, Germany). The skin 
wheal-flare reaction was read after 15  min and consid-
ered positive if the wheal diameter was at least 3  mm 
larger than one formed by the control substance.
Other laboratory investigations
The specific IgE to D. farinae and D. pteronyssinus were 
measured by ELISA using a commercial kit (Allergop-
harma, Reinbeck, Germany) according to the manufac-
turers’ instructions.
Statistical analysis
Data were delivered as medians and interquartile range 
(IQR). All the statistical evaluations were performed 
by Mann–Whitney U test. The correlations between 
parameters were measured with Spearman rank test. The 
results were considered significant when P < 0.05.
Results
No significant differences were found between PAR 
patients and healthy subjects with respect to plasma lev-
els of VEGF and its receptors (Table 1; Fig. 1). There were 
no significant correlations between values of VEGF and 
specific IgE to D. farinae and D. pteronyssinus (r = 0.244 
and r = 0.165, p > 0.05, respectively).
Discussion
Atopic diseases like asthma, rhinitis, and atopic dermati-
tis (AD) are characterised by local changes at the site of 
allergic processes, as well as systemic immune-inflam-
matory response. Similarities should be noted between 
various atopic diseases, but there are also differences, 
regarding the profiles of mediators released into the sys-
temic circulation [10].
So far, it has been reported that VEGF levels are 
increased in induced sputum and plasma/serum of asth-
matics; its overproduction may be implicated in chronic 
inflammation, asthma exacerbation, and the airway 
remodeling [11, 12]. In addition, it has been reported that 
patients with AD may show significantly increased con-
centration of VEGF in PPP [9]. It has been demonstrated 
that the vascular permeability of nasal mucosa was 
increased by VEGF [13] and this cytokine level in nasal 
discharge was significantly higher in patients with aller-
gic rhinitis sensitized by house dust mites and pollens 
than in nonallergic rhinosinusitis [14, 15]. In addition, 
VEGF serum concentrations were significantly lower in 
asymptomatic pollen-dependent AR patients studied 
outside the pollen season than in normal individuals. 
Interestingly, the VEGF concentrations increased after 
sublingual immunotherapy and were similar to values 
of normal subjects [16, 17]. We did not find any signifi-
cant differences in plasma levels of VEGF and its recep-
tors between PAR patients sensitized to house dust mites 
and the healthy subjects, suggesting that free circulating 
VEGF may not be elevated in the persistent allergy. On 
the basis of our own results as well as those reported by 
Ciprandi et al. [16, 17], it may be suggested that perma-
nent exposure to allergens, such as AR—induced by per-
sistent allergy (due to mites, mould or danders) or related 
to allergen immunotherapy are associated with normal 
VEGF concentration. However, confirmation of such 
hypothesis would demand evaluation of VEGF in symp-
tomatic patients with seasonal AR induced by pollens 
during the pollen season.
These findings, in conjunction with earlier data, indi-
cate that differences may exist in systemic VEGF release 
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between patients with distinct clinical manifestation of 
atopy.
Different cells involved in the pathogenesis of allergic 
inflammation are able to synthesize and release VEGF. 
Among them important storage site is formed by the 
platelets, which release VEGF upon activation in  vivo. 
The measurement of VEGF concentration in PPP is more 
reliable to assess in vivo free circulating VEGF, which is 
released from platelets and white blood cells during clot-
ting formation [18].
It has been reported that platelet activation measured 
by plasma concentration of platelet factor 4 and beta-
thromboglobulin is increased in AD patients, asthma, but 
not in allergic rhinitis and urticaria [10, 19–22]. Because 
platelets are important sources of VEGF in the circula-
tion, these findings have confirmed our earlier observa-
tions showing that enhanced platelet release reaction 
is not a phenomenon accompanying chronic allergic 
rhinitis.
Conclusions
Contrary to the previous studies indicating that VEGF 
level was increased in plasma of allergic patients suffering 
from asthma and atopic dermatitis, it seems that free cir-
culating VEGF may not be elevated in PAR patients.
Moreover, on the basis of the present study as well as the 
earlier ones, it appears likely that systemic release of VEGF 
varies among atopic patients and may depend first of all on 
severity/activity and the extent of inflammatory response.
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